SecProbe.io

Probe score transparency
Intelligence Terminal Search Topics Monthly Activity About

Probe Score Transparency

ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Score window: Apr. 15, 2025 to Apr. 14, 2026

Back View Correspondence
Probe Score
4.4 / 10
Letters
2
Latest Activity
Mar. 4, 2026
Version
v1

Score Breakdown

Letter Count
2.0
Sentiment / Tone
1.5
Keywords
0.0
Signals
0.0
Notable 8-K Modifier
0.9
Notable 8-K Count
2

Matched Signals

No stored keyword or signal matches were recorded for this score.

Filings In This Window

DateFormSentimentUrgencySummaryOpen
Jun. 17, 2025 UPLOAD Neutral/Informational Low The SEC has completed its review of Alnylam Pharmaceuticals, Inc.'s Form 10-K for the fiscal year ended December 31, 2024. The correspondence emphasizes the company's responsibili… Read Filing EDGAR
May. 22, 2025 CORRESP Concern from SEC Moderate The correspondence from Alnylam Pharmaceuticals, Inc. to the SEC addresses comments received regarding their Form 10-K for the year ended December 31, 2024. The SEC requested clar… Read Filing EDGAR
May. 9, 2025 UPLOAD Concern from SEC High The SEC has issued a comment letter to Alnylam Pharmaceuticals regarding their Form 10-K for the fiscal year ended December 31, 2024. The letter specifically requests clarificatio… Read Filing EDGAR

Notable 8-Ks In This Window

No notable 8-Ks were stored for this company in the score window.